Skip to main content

Table 2 Characteristics of patients in TDF+PI/r and control groups at the end of 48 weeeks a

From: Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study

Variable TDF+PI/r group (n=75) Control group (n=75) P
BMI b (kg/m 2 ) 21.9 (20.1-23.7) 21.0 (19.3-22.9) 0.083
CD4 cell count (cells/μl) 279 (196–380.5) 292.0 (207.0-394.0) 0.736
Viral load (log 10 copies/ml) 1.6 (1.6-1.8) 1.6 (1.6-1.7) 0.064
Proteinuria    0.071
  Positive 9 (12) 3(4)  
  Negative 66 (88) 72 (96)  
Serum creatinine (μmol/L) 79 (70–85) 69.7 (62–80.3) <0.001
eGFR c (ml/min/1.73 m 2 ) 93.0 (82.4-104.0) 101.6 (86.8-121.6) 0.009
Change in eGFR (ml/min/1.73 m 2 ) −8.8(−18.5-3.3) 6.4(−3.8-16.5) <0.001
  1. Note.
  2. aValues are expressed as median (interquartile range, IQR) or number (percentage).
  3. bBMI =weight (kg)/(height (m))2.
  4. ceGFR = 186 × (Serum creatinine (mg/dL))-1.154 × (age(years))-0.203 × (0.742 if female).